Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175674 | 0.93 | MAPK14 (0.72) | MAPK14MCHR1S1PR1PRKXACVR1 | |
| SCHEMBL2178986 | 0.87 | MAPK14 (0.56) | MAPK14MCHR1 | |
| SCHEMBL2177282 | 0.87 | MAPK14 (0.55) | MAPK14MCHR1 | |
| SCHEMBL2177202 | 0.85 | MAPK14 (0.53) | MAPK14MCHR1 | |
| SCHEMBL2180093 | 0.84 | MAPK14 (0.54) | MAPK14MCHR1 | |
| SCHEMBL2177300 | 0.84 | MAPK14 (0.72) | MAPK14MCHR1 | |
| SCHEMBL2178417 | 0.83 | MAPK14 (0.57) | MAPK14MCHR1S1PR1PRKXACVR1 | |
| SCHEMBL2176064 | 0.83 | MAPK14 (0.78) | MAPK14MCHR1S1PR1PRKXACVR1 | |
| SCHEMBL2176073 | 0.82 | MAPK14 (0.86) | MAPK14MCHR1 | |
| SCHEMBL2174901 | 0.82 | MAPK14 (0.56) | MAPK14MCHR1S1PR1PRKXACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | MAPK14 1791/4885MCHR1 4586/4885S1PR1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.